The multidisciplinary care required to treat these complex patients is most often found in higher-volume centers.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

Individuals assigned male at birth who were pushed to change their identity had more inflammation and higher blood pressure.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient ...

The novel CETP inhibitor, once tested for the now-defunct pathway of HDL raising, reduces LDL as well as Lp(a).

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...